

19 Oct 2021 | **News**

QUOTED. Jayson Bedford.

by

Results from Medtronic's pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system have been delayed until next year. Analyst Jayson Bedford of Raymond James Financial says the move may dent investor confidence.

“While the [renal denervation] opportunity is not lost, confidence in the program has now been dented.” – Jayson Bedford, analyst, Raymond James Financial

- Find out more: [Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022](#)

[Click here](#) for a free trial of *Medtech Insight*